Evidence map›Paper›PMID 19233916›Full record

ArticleClinical chemistry2009

Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.

Jin Li, Lilin Wang, Pasi A Jänne, G Mike Makrigiorgos

Open access · bronzeAbstract read
In one paragraph

Article in Clinical chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jin LiDepartment of Radiation Oncology, Divisions of Genomic Stability and DNA Repair, and Medical Physics, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Lilin Wang
Pasi A Jänne
G Mike Makrigiorgos
Dana-Farber Cancer Institute · US

Funding

RADIATION BIOLOGY TRAINING PROGRAMT32CA009078 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI D'ANDREA, ALAN D. · 1985 to 2009
$4.6M
Drug Resistance in Lung CancerR01CA135257 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2008 to 2017
$3.5M
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATIONR33CA111994 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2007 to 2008
$656k
CIRCULATING DNA AMPLIFICATION & COLON CA DETECTIONR21CA115439 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. M · 2006 to 2007
$353k
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATIONR21CA111994 · NCI · DANA-FARBER CANCER INSTITUTE · PI MAKRIGIORGOS, G. MIKE · 2005 to 2006
$290k
NCI NIH HHS 5 T32 CA09078NCI NIH HHS CA-111994NCI NIH HHS CA-115439NCI NIH HHS R01 CA135257NCI NIH HHS R21 CA111994NCI NIH HHS R21 CA115439NCI NIH HHS R33 CA111994NCI NIH HHS T32 CA009078
6 · The paper itself

Abstract

backgroundDNA genotyping with mutation-specific TaqMan(R) probes (Applied Biosystems) is broadly used in detection of single-nucleotide polymorphisms but is less so for somatic mutations because of its limited selectivity for low-level mutations. We recently described coamplification at lower denaturation temperature-PCR (COLD-PCR), a method that amplifies minority alleles selectively from mixtures of wild-type and mutation-containing sequences during the PCR. We demonstrate that combining COLD-PCR with TaqMan technology provides TaqMan genotyping with the selectivity needed to detect low-level somatic mutations.

methodsMinor-groove binder-based or common TaqMan probes were designed to contain a nucleotide that matches the desired mutation approximately in the middle of the probe. The critical denaturation temperature (T(c)) of each amplicon was then experimentally determined. COLD-PCR/TaqMan genotyping was performed in 2 steps: denaturation at the T(c), followed by annealing and extension at a single temperature (fast COLD-PCR). The threshold cycle was used to identify mutations on the basis of serial dilutions of mutant DNA into wild-type DNA and to identify TP53 (tumor protein p53) and EGFR [epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)] mutations in tumors.

resultsCOLD-PCR/TaqMan genotyping identified G>A mutations within TP53 exon 8 (codon 273 mutation hot spot) and C>T mutations within the EGFR gene (drug-resistance mutation T790M) with a selectivity improvement of 15- to 30-fold over regular PCR/TaqMan genotyping. A second round of COLD-PCR/TaqMan genotyping improved the selectivity by another 15- to 30-fold and enabled detection of 1 mutant in 2000 wild-type alleles. Use of COLD-PCR/TaqMan genotyping allowed quantitative identification of low-level TP53 and T790 mutations in colon tumor samples and in non-small-cell lung cancer cell lines treated with kinase inhibitors.

conclusionsThe major improvement in selectivity provided by COLD-PCR enables the popular TaqMan genotyping method to become a powerful tool for detecting low-level mutations in clinical samples.

Indexed as

TemperatureCell Line, TumorDNA ProbesExonsGenotypeHumansMaleMutationNucleic Acid DenaturationPolymerase Chain ReactionTime FactorsTumor Suppressor Protein p53DNA ProbesTumor Suppressor Protein p53

Identifiers

PMID19233916
PMCPMC2754313
OpenAlexW2104669758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.